The presence of Hypoxic cells in a tumor decreases their radiosensitivity; which blocks the efficacy of external tele cobalt irradiation. So a study was undertaken in various cancer patients to observe the role of metrnidazole as a selective radiosensitizer. 717 cancer cases were enlisted and were divided into a study and control group. The study group were given metronidazole at a dose of 2 grams orally, 4 hours before each irradiation, (5 days in a week) for 6-7 weeks. The control group were devoid of it. After completion of the treatment, as well as, after 3 years follow-up, it was observed that the patients receiving metronidazole had better treatment response and more number of recurrence free years. Since it is a cheaper drug it can be used freely in the form of a potential radiosensitizer, for external irradiation therapy.

[ABSTRACT]   Full text not available    [CITATIONS]  [PubMed]

Full text not available     [PubMed]

Full text not available     [PubMed]

Immunomodulators have opened new vistas in the management of the immunocompromised patient. They have been shown to enhance the efficacy of vaccines in infections, head and neck malignancy, the immunosuppressed and recently in AIDS. The mechanism of their action is discussed. They hold promise of further advances in immunotherapy.

[ABSTRACT]   Full text not available     [PubMed]